Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.

Humans Male Prospective Studies Prostatic Neoplasms / radiotherapy Radiosurgery / methods Retrospective Studies
Prostatic Neoplasms Prostatic Neoplasms /radiotherapy Radiosurgery/methods Radiotherapy Dosage

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
May 2022
Historique:
received: 04 06 2020
revised: 25 01 2022
accepted: 21 03 2022
pubmed: 29 3 2022
medline: 3 5 2022
entrez: 28 3 2022
Statut: ppublish

Résumé

Stereotactic body radiotherapy (SBRT) has become treatment option for localized prostate cancer but the evidence base remains incomplete. Several clinical studies, both prospective and retrospective, have been published. However, treatment techniques, target volumes and dose constraints lack consistency between studies. Based on the current available literature, the French Genito-Urinary Group (GETUG) suggests that.

Identifiants

DOI: 10.1016/j.critrevonc.2022.103661 PMID: 35341986
pubmed: 35341986
pii: S1040-8428(22)00085-3
doi: 10.1016/j.critrevonc.2022.103661
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103661

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Ariane Lapierre (A)

Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France.

Christophe Hennequin (C)

Department of Radiation Oncology, Hôpital Saint-Louis, 75475 Paris, France.

Amandine Beneux (A)

Service de Physique Médicale et de Radioprotection, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.

Sarah Belhomme (S)

Radiation Oncology Department, Bergonie Institute, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France.

Nicolas Benziane Ouaritini (N)

Radiation Oncology Department, Bergonie Institute, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: Nicolasbenziane@hotmail.fr.

Marie-Claude Biston (MC)

Léon Bérard Cancer Center, University of Lyon, France; Université de Lyon, CREATIS, CNRS UMR5220, Inserm, U1044 INSA, Lyon, France.

Gilles Crehange (G)

Département de radiothérapie oncologique, institut Curie, 26, rue d'Ulm, 75005 Paris, France.

Renaud de Crevoisier (R)

Département de Radiothérapie, Centre Eugène Marquis, Rennes, France.

Jean-Luc Dumas (JL)

Institut Curie, Radiotherapy department / Medical physics, 26 rue d'Ulm, 75005 cedex Paris, France.

Maher Fawzi (M)

Institut Curie, Site Saint Cloud, Service de Radiotherapie, 35, rue Dailly, 92210 Saint Cloud, France.

Albert Lisbona (A)

Medical Physics Department Institut de Cancérologie de l'Ouest, Bd J. Monod, 44805 Saint Herblain, France.

David Pasquier (D)

Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille; CRIStAL UMR, 9189 Lille, France.

Sandra Pelissier (S)

GETUG Group, Unicancer, Paris, France.

Pierre Graff-Cailleaud (P)

University Institute of Cancer Toulouse-Oncopôle, Toulouse, France.

Pascal Pommier (P)

Radiotherapy Department, Centre Léon Bérard, Lyon, France.

Paul Sargos (P)

Radiation Oncology Department, Bergonie Institute, Bordeaux, France.

Jean-Marc Simon (JM)

Department of Radiotherapy, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France.

Stéphane Supiot (S)

Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, St-Herblain, France.

Florence Tantot (F)

GETUG Group, Unicancer, Paris, France.

Olivier Chapet (O)

Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France. Electronic address: olivier.chapet@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Highly hypofractionated schedules for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Highly hypofractionated schedules for...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Highly hypofractionated schedules for...
questionsmedicales.fr › Techniques d'investigation › Techniques stéréotaxiques › Radiochirurgie › Highly hypofractionated schedules for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Highly hypofractionated schedules for...